Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments

Rajendran J.C. Bose, Soo Hong Lee, Hansoo Park

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations

Abstract

Biological barriers, such as phagocytosis and nonspecific distribution, are major factors limiting the clinical translation of nanomedicine. Biomimetic and bioengineering strategies have been used to overcome these challenges. In particular, natural cell membrane-based biofunctionalized nanoparticles (CMFNPs) have gained widespread attention owing to their cell surface mimetic characteristics and tailored nanomaterial features. These hybrid nanocarriers show strong potential for the delivery of myriad therapeutic agents. Herein, we highlight the most recent advances in CMFNP-based drug delivery systems and address the challenges and opportunities in the field.

Original languageEnglish
Pages (from-to)1303-1312
Number of pages10
JournalDrug Discovery Today
Volume21
Issue number8
DOIs
StatePublished - 1 Aug 2016

Fingerprint

Dive into the research topics of 'Biofunctionalized nanoparticles: an emerging drug delivery platform for various disease treatments'. Together they form a unique fingerprint.

Cite this